Andrew Guggenhime Sells 10,000 Shares of Vaxcyte (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 10,000 shares of Vaxcyte stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $53.89, for a total transaction of $538,900.00. Following the completion of the sale, the chief financial officer directly owned 105,176 shares of the company’s stock, valued at $5,667,934.64. The trade was a 8.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime also recently made the following trade(s):

• On Monday, July 6th, Andrew Guggenhime sold 10,000 shares of Vaxcyte stock. The stock was sold at an average price of $57.28, for a total value of $572,800.00.
• On Thursday, June 18th, Andrew Guggenhime sold 10,000 shares of Vaxcyte stock. The stock was sold at an average price of $53.00, for a total value of $530,000.00.

Vaxcyte Trading Up 5.3%

Vaxcyte stock opened at $58.89 on Friday. The firm has a market capitalization of $8.50 billion, a P/E ratio of -7.72 and a beta of 1.23. The stock has a fifty day moving average price of $53.72 and a 200 day moving average price of $55.19. Vaxcyte, Inc. has a 52 week low of $29.08 and a 52 week high of $65.00.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.09. During the same period last year, the business earned ($1.22) earnings per share. As a group, equities analysts predict that Vaxcyte, Inc. will post -7.91 EPS for the current year.

Institutional Trading of Vaxcyte

Several large investors have recently added to or reduced their stakes in PCVX. Smartleaf Asset Management LLC grew its position in Vaxcyte by 156.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after acquiring an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Vaxcyte by 1,463.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after purchasing an additional 600 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Vaxcyte by 33.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after purchasing an additional 184 shares in the last quarter. CIBC Private Wealth Group LLC grew its holdings in Vaxcyte by 22,500.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after purchasing an additional 1,350 shares in the last quarter. Finally, Capital Advisors Ltd. LLC purchased a new stake in Vaxcyte during the 1st quarter worth $58,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PCVX shares. Zacks Research downgraded shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Finally, Wall Street Zen cut Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $86.00.

Trending Headlines about Vaxcyte

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Quarterly loss beat expectations: Vaxcyte reported second-quarter 2026 EPS of negative $1.97, better than analysts’ consensus estimate of negative $2.06. However, the loss was wider than the negative $1.22 reported in the year-earlier quarter. Vaxcyte quarterly earnings release
• Positive Sentiment: Multiple clinical catalysts are ahead: Topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial are expected in the fourth quarter of 2026. Results from OPUS-2 and OPUS-3 are expected in the first half of 2027, while infant VAX-31 data are expected by the end of the first half of 2027. Vaxcyte second-quarter business update
• Positive Sentiment: Strong liquidity supports development: Vaxcyte held approximately $2.5 billion in cash, cash equivalents and investments at June 30, 2026. The balance sheet reduces near-term financing concerns as the company advances its late-stage vaccine programs and VAX-A1.
• Neutral Sentiment: Institutional ownership remains high: Several funds, including Royal Bank of Canada, UBS Asset Management and Cetera Investment Advisers, increased their positions recently. Institutional investors and hedge funds collectively own approximately 96.8% of outstanding shares.
• Negative Sentiment: Executives reported stock sales: The CFO, COO and another insider sold a combined 29,250 shares worth roughly $1.6 million. The transactions were made under pre-arranged Rule 10b5-1 plans, limiting their significance, but the sales may still weigh modestly on sentiment. Vaxcyte insider selling report
• Negative Sentiment: Losses are expected to continue: Analysts forecast a full-year 2026 loss of approximately $7.91 per share, underscoring Vaxcyte’s dependence on successful clinical execution and future commercialization.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.